Name (Synonyms) | Correlation | |
---|---|---|
drug573 | Ciclesonide Metered Dose Inhaler [Alvesco] Wiki | 0.71 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D001714 | Bipolar Disorder NIH | 0.71 |
D003865 | Depressive Disorder, Major NIH | 0.41 |
D003866 | Depressive Disorder NIH | 0.33 |
D003863 | Depression, NIH | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100754 | Mania HPO | 0.71 |
HP:0000716 | Depressivity HPO | 0.33 |
There are 2 clinical trials
The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.
Description: Less than or equal to 10
Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in HRSD-24 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on HRSD-24 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4
Measure: Remission on Patient Health Questionnaire (PHQ-9) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on PHQ-9 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in PHQ-9 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4
Measure: Remission on General Anxiety Disorder 7 item (GAD-7) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on GAD-7 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in GAD-7 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 12
Measure: Remission on Beck Depression Inventory (BDI-II) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in Score
Measure: Response on BDI-II Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change on BDI-II Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Score of 0
Measure: Remission on Beck Scale for Suicidal Ideation (SSI) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change on SSI Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in WHO Disability Assessment Schedule (WHODAS) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Includes number of treatment days needed and number going on to receive ECT
Measure: Proportion of Patients Maintaining Response During Relapse Prevention Time: 24 weeks (Tapering and Relapse prevention phase)The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose LFR protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with bipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.
Description: Less than or equal to 10 This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Change in Hamilton Rating Scale for Depresion 24-it (HRSD-24) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-76 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Response on Hamilton Rating Scale for Depresion 24-it (HRSD-24) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to quantify the severity of symptoms of mania Scale range: 0-60 (total score) Lower scores indicate lower severity of manic symptoms (i.e., better outcome) Higher scores indicate higher severity of manic symptoms (i.e., worse outcome)
Measure: Change in Young Mania Rating Scale (YMRS) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Remission on Patient Health Questionnaire (PHQ-9) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Response on Patient Health Questionnaire (PHQ-9) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-27 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Change in Patient Health Questionnaire (PHQ-9) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4 This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)
Measure: Remission on General Anxiety Disorder 7 item (GAD-7) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)
Measure: Response on General Anxiety Disorder 7 item (GAD-7) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to quantify the severity of symptoms of anxiety Scale range: 0-21 (total score) Lower scores indicate lower severity of anxiety symptoms (i.e., better outcome) Higher scores indicate higher severity of anxiety symptoms (i.e., worse outcome)
Measure: Change in General Anxiety Disorder 7 item (GAD-7) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 12 This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Remission on Beck Depression Inventory (BDI-II) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in Score This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Response on Beck Depression Inventory (BDI-II) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to quantify the severity of symptoms of depression Scale range: 0-63 (total score) Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome)
Measure: Change on Beck Depression Inventory (BDI-II) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Score of 0 This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)
Measure: Remission on Beck Scale for Suicidal Ideation (SSI) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores This scale is used to assess the presence or absence of suicidal ideation and the degree of severity of suicidal ideas Scale range: 0 - 38 (total score) Lower scores indicate lower severity of suicidal ideation (i.e., better outcome) Higher scores indicate higher severity of suicidal ideation (i.e., worse outcome)
Measure: Change on Beck Scale for Suicidal Ideation (SSI) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in WHO Disability Assessment Schedule (WHODAS) Range 0-38 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Includes number of treatment days needed and number going on to receive ECT
Measure: Proportion of Patients Maintaining Response During Relapse Prevention Time: 24 weeks (Tapering and Relapse prevention phase)